IP Library Patent Application 15309417
Patent Application
App. No. 15/309,417

METHOD FOR TREATING RENAL CELL CARCINOMA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/309,417
Abstract

Accordingly, the present invention provides a method of treating kidney neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.

Claims (11)

1 . A method for treating a kidney neoplasia in a subject in need of treatment comprising the step of: administering to the kidney neoplasia an amount of microparticles that delivers a radiation dose between 100 and 600Gy.

2 . A method of treatment for renal neoplastic conditions in a subject comprising subjecting the subject to SIRT, wherein (i) the prescribed activity of the irradiated microparticles used in the selective internal radiation therapy is 0.02 to 3.5 GBq and (ii) the therapy delivers between 75 and 800 Gy to the site of treatment in the kidney.

3 . A method according to claim 1 wherein the microparticles are suitable for selective internal radiation therapy.

4 . A method according to claim 1 wherein the microparticles have a level of radioactivity that is between about 0.02 to 3.5 GBq.

5 . A method according to claim 3 wherein the radioactivity is capped at a maximum of 3 GBq.

6 . A method according to claim 1 wherein the radioactivity of the microparticles used in the SIRT is calculated by determining the tumour volume and then adjusting the amount of the radioactive microparticles, having regard to tumour volume, to deliver to the kidney neoplasia a radiation dose between 100 and 600Gy.

7 . A method according to claim 1 wherein the microparticles are irradiated with yttrium-90.

8 . A method according to claim 2 wherein the microparticles are suitable for selective internal radiation therapy.

9 . A method according to claim 8 wherein the radioactivity is capped at a maximum of 3 GBq.

10 . A method according to claim 2 wherein the radioactivity of the microparticles used in the SIRT is calculated by determining the tumour volume and then adjusting the amount of the radioactive microparticles, having regard to tumour volume, to deliver to the kidney neoplasia a radiation dose between 100 and 600Gy.

11 . A method according to claim 2 wherein the microparticles are irradiated with yttrium-90.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2024
From: CHINA CITIC BANK INTERNATIONAL LIMITED
To: GRAND PHARMA SPHERE (AUSTRALIA BIDCO) PTY LTD; SIRTEX MEDICAL PTY LTD; SIRTEX MEDICAL PRODUCTS PTY LTD; SIRTEX GLOBAL PTY LTD; SIRTEX TECHNOLOGY PTY LTD
Reel/Frame 067944/0310 →
SECURITY INTEREST Recorded Jun 16, 2022
From: GRAND PHARMA SPHERE (AUSTRALIA BIDCO) PTY LTD; SIRTEX MEDICAL PTY LTD; SIRTEX MEDICAL PRODUCTS PTY LTD; SIRTEX GLOBAL PTY LTD; SIRTEX TECHNOLOGY PTY LTD
To: CHINA CITIC BANK INTERNATIONAL LIMITED
Reel/Frame 060450/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2019
From: CADE, DAVID
To: SIRTEX MEDICAL LIMITED
Reel/Frame 048777/0150 →
SECURITY INTEREST Recorded Nov 30, 2018
From: SIRTEX MEDICAL LIMITED
To: BANK OF CHINA LIMITED MACAU BRANCH
Reel/Frame 047691/0520 →